Association of 1,5-anhydroglucitol with diabetes and microvascular conditions

Elizabeth Selvin, Andreea M. Rawlings, Morgan Grams, Ronald Klein, Michael W Steffes, Josef Coresh

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is inversely related to hyperglycemia and may be a useful indicator of short-term (1-2 weeks) hyperglycemia and glycemic excursions, but its prognostic value is unclear. We sought to evaluate the associations of 1,5-AG with risk of diabetes and microvascular disease.

METHODS: Wemeasured 1,5-AG in blood samples from over 10000 participants in the ARIC (Atherosclerosis Risk in Communities) Study (baseline, 1990-1992) and characterized the independent associations with prevalent retinopathy and with incident chronic kidney disease and incident diabetes during approximately 20 years of follow-up.

RESULTS: We found that 1,5-AG was associated with prevalent retinopathy, driven primarily by the strong association in persons with diagnosed diabetes: adjusted odds ratio (OR) 11.26 (95% CI, 6.17-20.53) for <6 μg/mL compared to 1,5-AG ≥10 μg/mL. This result remained significant after further adjustment for hemoglobin A1c (Hb A1c) (OR, 4.85; 95% CI, 2.42-9.74). In persons with diagnosed diabetes, low 1,5-AG (<6 μg/mL vs ≥10 μg/mL) was also associated with a >2-fold increased risk of incident chronic kidney disease [adjusted hazard ratio (HR), 2.83; 95% CI, 2.15-3.74] and remained significant after adjustment for Hb A1c (HR, 1.43; 95% CI, 1.02-2.00). Nondiabetic participants with high 1,5-AG (≥10 μg/mL) had the lowest prevalence of retinopathy and lowest risk of kidney disease. In persons without diagnosed diabetes at baseline, 1,5-AG <10 μg/mL was also associated with incident diabetes (adjusted HR, 2.29; 95% CI, 2.03-2.58).

CONCLUSIONS: 1,5-AG was associated with long-term risk of important microvascular outcomes, particularly in persons with diagnosed diabetes and even after adjustment for Hb A1c. Our results suggest 1,5-AG may capture risk information associated with hyperglycemic excursions.

Original languageEnglish (US)
Pages (from-to)1409-1418
Number of pages10
JournalClinical chemistry
Volume60
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Medical problems
Hazards
Glycosylated Hemoglobin A
Chronic Renal Insufficiency
Hyperglycemia
1,5-anhydroglucitol
Kidney Diseases
Atherosclerosis
Blood
Odds Ratio

Cite this

Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. / Selvin, Elizabeth; Rawlings, Andreea M.; Grams, Morgan; Klein, Ronald; Steffes, Michael W; Coresh, Josef.

In: Clinical chemistry, Vol. 60, No. 11, 01.11.2014, p. 1409-1418.

Research output: Contribution to journalArticle

Selvin, Elizabeth ; Rawlings, Andreea M. ; Grams, Morgan ; Klein, Ronald ; Steffes, Michael W ; Coresh, Josef. / Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. In: Clinical chemistry. 2014 ; Vol. 60, No. 11. pp. 1409-1418.
@article{85963ba354f542e89ab60de415b9ca3b,
title = "Association of 1,5-anhydroglucitol with diabetes and microvascular conditions",
abstract = "BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is inversely related to hyperglycemia and may be a useful indicator of short-term (1-2 weeks) hyperglycemia and glycemic excursions, but its prognostic value is unclear. We sought to evaluate the associations of 1,5-AG with risk of diabetes and microvascular disease.METHODS: Wemeasured 1,5-AG in blood samples from over 10000 participants in the ARIC (Atherosclerosis Risk in Communities) Study (baseline, 1990-1992) and characterized the independent associations with prevalent retinopathy and with incident chronic kidney disease and incident diabetes during approximately 20 years of follow-up.RESULTS: We found that 1,5-AG was associated with prevalent retinopathy, driven primarily by the strong association in persons with diagnosed diabetes: adjusted odds ratio (OR) 11.26 (95{\%} CI, 6.17-20.53) for <6 μg/mL compared to 1,5-AG ≥10 μg/mL. This result remained significant after further adjustment for hemoglobin A1c (Hb A1c) (OR, 4.85; 95{\%} CI, 2.42-9.74). In persons with diagnosed diabetes, low 1,5-AG (<6 μg/mL vs ≥10 μg/mL) was also associated with a >2-fold increased risk of incident chronic kidney disease [adjusted hazard ratio (HR), 2.83; 95{\%} CI, 2.15-3.74] and remained significant after adjustment for Hb A1c (HR, 1.43; 95{\%} CI, 1.02-2.00). Nondiabetic participants with high 1,5-AG (≥10 μg/mL) had the lowest prevalence of retinopathy and lowest risk of kidney disease. In persons without diagnosed diabetes at baseline, 1,5-AG <10 μg/mL was also associated with incident diabetes (adjusted HR, 2.29; 95{\%} CI, 2.03-2.58).CONCLUSIONS: 1,5-AG was associated with long-term risk of important microvascular outcomes, particularly in persons with diagnosed diabetes and even after adjustment for Hb A1c. Our results suggest 1,5-AG may capture risk information associated with hyperglycemic excursions.",
author = "Elizabeth Selvin and Rawlings, {Andreea M.} and Morgan Grams and Ronald Klein and Steffes, {Michael W} and Josef Coresh",
year = "2014",
month = "11",
day = "1",
doi = "10.1373/clinchem.2014.229427",
language = "English (US)",
volume = "60",
pages = "1409--1418",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Association of 1,5-anhydroglucitol with diabetes and microvascular conditions

AU - Selvin, Elizabeth

AU - Rawlings, Andreea M.

AU - Grams, Morgan

AU - Klein, Ronald

AU - Steffes, Michael W

AU - Coresh, Josef

PY - 2014/11/1

Y1 - 2014/11/1

N2 - BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is inversely related to hyperglycemia and may be a useful indicator of short-term (1-2 weeks) hyperglycemia and glycemic excursions, but its prognostic value is unclear. We sought to evaluate the associations of 1,5-AG with risk of diabetes and microvascular disease.METHODS: Wemeasured 1,5-AG in blood samples from over 10000 participants in the ARIC (Atherosclerosis Risk in Communities) Study (baseline, 1990-1992) and characterized the independent associations with prevalent retinopathy and with incident chronic kidney disease and incident diabetes during approximately 20 years of follow-up.RESULTS: We found that 1,5-AG was associated with prevalent retinopathy, driven primarily by the strong association in persons with diagnosed diabetes: adjusted odds ratio (OR) 11.26 (95% CI, 6.17-20.53) for <6 μg/mL compared to 1,5-AG ≥10 μg/mL. This result remained significant after further adjustment for hemoglobin A1c (Hb A1c) (OR, 4.85; 95% CI, 2.42-9.74). In persons with diagnosed diabetes, low 1,5-AG (<6 μg/mL vs ≥10 μg/mL) was also associated with a >2-fold increased risk of incident chronic kidney disease [adjusted hazard ratio (HR), 2.83; 95% CI, 2.15-3.74] and remained significant after adjustment for Hb A1c (HR, 1.43; 95% CI, 1.02-2.00). Nondiabetic participants with high 1,5-AG (≥10 μg/mL) had the lowest prevalence of retinopathy and lowest risk of kidney disease. In persons without diagnosed diabetes at baseline, 1,5-AG <10 μg/mL was also associated with incident diabetes (adjusted HR, 2.29; 95% CI, 2.03-2.58).CONCLUSIONS: 1,5-AG was associated with long-term risk of important microvascular outcomes, particularly in persons with diagnosed diabetes and even after adjustment for Hb A1c. Our results suggest 1,5-AG may capture risk information associated with hyperglycemic excursions.

AB - BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is inversely related to hyperglycemia and may be a useful indicator of short-term (1-2 weeks) hyperglycemia and glycemic excursions, but its prognostic value is unclear. We sought to evaluate the associations of 1,5-AG with risk of diabetes and microvascular disease.METHODS: Wemeasured 1,5-AG in blood samples from over 10000 participants in the ARIC (Atherosclerosis Risk in Communities) Study (baseline, 1990-1992) and characterized the independent associations with prevalent retinopathy and with incident chronic kidney disease and incident diabetes during approximately 20 years of follow-up.RESULTS: We found that 1,5-AG was associated with prevalent retinopathy, driven primarily by the strong association in persons with diagnosed diabetes: adjusted odds ratio (OR) 11.26 (95% CI, 6.17-20.53) for <6 μg/mL compared to 1,5-AG ≥10 μg/mL. This result remained significant after further adjustment for hemoglobin A1c (Hb A1c) (OR, 4.85; 95% CI, 2.42-9.74). In persons with diagnosed diabetes, low 1,5-AG (<6 μg/mL vs ≥10 μg/mL) was also associated with a >2-fold increased risk of incident chronic kidney disease [adjusted hazard ratio (HR), 2.83; 95% CI, 2.15-3.74] and remained significant after adjustment for Hb A1c (HR, 1.43; 95% CI, 1.02-2.00). Nondiabetic participants with high 1,5-AG (≥10 μg/mL) had the lowest prevalence of retinopathy and lowest risk of kidney disease. In persons without diagnosed diabetes at baseline, 1,5-AG <10 μg/mL was also associated with incident diabetes (adjusted HR, 2.29; 95% CI, 2.03-2.58).CONCLUSIONS: 1,5-AG was associated with long-term risk of important microvascular outcomes, particularly in persons with diagnosed diabetes and even after adjustment for Hb A1c. Our results suggest 1,5-AG may capture risk information associated with hyperglycemic excursions.

UR - http://www.scopus.com/inward/record.url?scp=84908614913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908614913&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2014.229427

DO - 10.1373/clinchem.2014.229427

M3 - Article

C2 - 25200356

AN - SCOPUS:84908614913

VL - 60

SP - 1409

EP - 1418

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -